Mcl-1, vascular endothelial growth factor-R2, and 14-3-3σ expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8632-8636

  Erovic, Boban M ^a   Pelzmann, Martina ^a   Grasl, Matthäus Ch ^a   Pammer, Johannes ^a   Kornek, Gabriela ^a   Brannath, Werner ^a   Selzer, Edgar ^a   Thurnher, Dietmar ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; CISPLATIN; MITOMYCIN C; PROTEIN 14 3 3; PROTEIN MCL 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; EXONUCLEASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 29344471814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1170     Document Type: Article

References (42)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Gath HJ, Brakenhoff RH. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 1999; 18:109-26.
3. Hannisdal K, Boysen M, Evensen JF. Different prognostic indices in 310 patients with tonsillar carcinomas. Head Neck 2003;25:123-31.
4. Hall SF, Groome PA, Rothwell D, Dixon PF. Using the TNM system to predict survival in squamous cell carcinoma of the head and neck. Anticancer Res 1998;18: 4777-8.
5. Hassan KA, Ang KK, El-Naggar AK, et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002;62:6414-7.
6. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
7. Smith BD, Haffty BG. Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 1999;7:125-44.
8. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000;12:229-39.
9. Carlos de Vicente J, Junquera Gutierrez LM, Zapatero AH, Fresno Forcelledo MF, Hernandez-Vallejo G, Lopez Arranz JS. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck 2004;26:22-30.
10. Li W, Thompson CH, Cossart YE, et al. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil, Head Neck 2004;26:1-9.
11. Wilson GD, Saunders MI, Dische S, Richman PI, Daley FM, Bentzen SM. Bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. Int J Radiat Oncol Biol Phys 2001;49:435-41.
12. Costa A, Licitra L, Veneroni S, et al. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer 1998;79:619-23.
13. Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene 1998;17:3207-13.
14. Boucher MJ, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79: 355-69.
15. Yang T, Buchan HL, Townsend KJ, et al. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 1996;166:523-36.
16. Itoh T, Itoh A, Pleasure D. Bcl-2-related protein family gene expression during oligodendraglial differentiation. J Neurochem 2003;85:1500-12.
17. Craig RW. The Bcl-2 gene family. Semin Cancer Biol 1995;6:35-43.
18. Klampfer L, Zhang J, Mimer SD. GM-CSF rescues T1 cells from growth factor withdrawal-induced, but not differentiation-induced apoptosis: the role of Bcl-2 and Mcl-1. Cytokine 1999;11:849-55.
19. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001;111:1834-41.
20. Neuchrist C, Quint C, Pammer A, Burian M. Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol 1999; 119:732-8.
21. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003; 25:464-74.
22. Erovic BM, Pammer J, Hollemann D, et al. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 2003;25: 848-57.
23. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401: 616-20.
24. Cheng L, Pan CX, Zhang JT, et al. N. Loss of 14-3-3σ in prostate cancer and its precursors. Clin Cancer Res 2004;10:3064-8.
25. Gasco M, Bell AK, Heath V, et al. Epigenetic inactivation of 14-3-3σ in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 2002;62:2072-6.
26. Hotz MA, Bosq J, Zbaeren P, et al. Spontaneous apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1999; 125:417-22.
27. Skvara H, Thallinger C, Wachek V, et al. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death. Anticancer Res 2005;25:2697-703.
28. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 2001;61:2413-9.
29. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor re-growth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16.
30. Abdollahi A, Lipson KE, Han X, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003;63;3755-63.
31. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperf ractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
32. Lemaire F, Millon R, Young J, et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2003;89:1940-9.
33. El-Naggar AK, Kim HW, Clayman GL, et al. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene 2002;21:8206-19.
34. Leethanakul C, Knezevic V, Patel V, et al. Head and Neck Cancer Genome Anatomy Project. Gene discovery in oral squamous cell carcinoma through the Head and Neck Cancer Genome Anatomy Project: confirmation by microarray analysis. Oral Oncol 2003;39: 248-58.
35. Al Moustafa AE, Alaoui-Jamali MA, Batist G, et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002;21:2634-40.
36. Gallo O, Boddi V, Calzolari A, et al. bcl-2 protein expression correlates with recurrence, and survival in early stage head, and neck cancer treated by radiotherapy. Clin Cancer Res 1996;2:261-7.
37. Homma A, Furuta Y, Oridate N, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clinical Cancer Res 1999;5:801-6.
38. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
39. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-7.
40. Chu K, Teele N, Dewey MW, Albright N, Dewey WC. Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3σ and CDKN1A (p21) knockout cell lines. Radiat Res 2004;162:270-86.
41. Thallinger C, Wolschek MF, Maierhofer H, et al. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 2004;10:4185-91.
42. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radio-therapy. Clin Cancer Res 2004;10:3745-54.